



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

APRI (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$0.95
Change (%)	▼ 0.02 (2.06%)
Volume	200,544
52 Week High	\$5.95
52 Week Low	\$0.95
Market Cap	\$7,501,209
Rolling EPS	-1.21
PE Ratio	0
Shares Outstanding	7,733,205

Data as of 05/25/17 12:27 p.m. ET



Recent Headlines

05/11/17
[Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results](#)

05/04/17
[Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study](#)

05/04/17
[Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/18/17	8-K
05/11/17	DEFA14A
05/11/17	10-Q
05/11/17	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.